Adiponectin protects against the development of systolic dysfunction following myocardial infarction

Rei Shibata1, Yasuhiro Izumiya, Kaori Sato

  • 1Molecular Cardiology/Whitaker Cardiovascular Institute, Boston University School of Medicine, 715 Albany Street, W611, Boston, MA 02118, USA.

Insights

Adiponectin protects the heart after myocardial infarction by reducing cardiac remodeling and improving function. This study shows adiponectin deficiency worsens heart failure, while supplementation improves outcomes.

Area of Science:

  • Cardiology
  • Endocrinology
  • Molecular Biology

Background:

  • Obesity is linked to heart failure with left ventricular (LV) dysfunction.
  • Adiponectin, an adipocyte hormone, is reduced in obesity.
  • The role of adiponectin in cardiac remodeling post-myocardial infarction (MI) is unclear.

Purpose of the Study:

  • To investigate the function of adiponectin in cardiac remodeling following myocardial infarction.
  • To assess the effects of adiponectin deficiency and supplementation on cardiac structure and function.

Main Methods:

  • Myocardial infarction induced in adiponectin-deficient (APN-KO) and wild-type (WT) mice via LAD ligation.
  • Adenoviral vectors used for systemic adiponectin or beta-galactosidase delivery.
  • Cardiac function assessed by echocardiography and Millar catheterization; histological analysis for capillary density, apoptosis, and fibrosis.

Main Results:

  • APN-KO mice exhibited worsened LV dilation, hypertrophy, and contractile dysfunction post-MI compared to WT mice.
  • APN-KO mice showed increased myocyte apoptosis, interstitial fibrosis, and reduced capillary density.
  • Adiponectin administration in WT mice improved LV function, reduced hypertrophy, apoptosis, and fibrosis, and increased capillary density.

Conclusions:

  • Adiponectin plays a protective role against systolic dysfunction after myocardial infarction.
  • Adiponectin mitigates cardiac remodeling by suppressing hypertrophy, fibrosis, and cell loss.
  • Targeting adiponectin may be a therapeutic strategy for post-myocardial infarction recovery.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...